Journal: Frontiers in Oncology

Article Title: Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion

doi: 10.3389/fonc.2023.1147974

Figure Lengend Snippet: Morphologic features and IHC staining of the uterine IMT samples. Representative pictures of H&E staining (A) and IHC analysis (B) of ALK, AE1/3, PR, and caldesmon expression levels in uterine IMT. Scale bars are illustrated in the pictures. IHC, immunohistochemistry; IMT, inflammatory myofibroblastic tumor; H&E, hematoxylin, and eosin.

Article Snippet: Sectioned tissues were then performed for hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) staining with ALK (Cat. # 3633S, Cell Signaling Technology, Danvers, MA, USA), AE1/3 (Cat. # 67306S, Cell Signaling Technology), PR (Cat. # 8757S, Cell Signaling Technology), and caldesmon (Cat. # ab183339, Abcam, Cambridge, UK).

Techniques: Immunohistochemistry, Staining, Expressing

Journal: bioRxiv

Article Title: Establishment and Characterization of Three Novel CAF Cell Lines from HNSCC Patients

doi: 10.1101/2023.01.08.523131

Figure Lengend Snippet: Purity of established cell lines. (A) FACS analysis displaying EpCAM and FSP-1 staining for the established cell lines. (B) Fluorescent images of established cell lines stained with F P-1, EpCAM, CD31, and CD45 (Magnification 10X, Scale bar-50μm). (C) FACS analysis displaying CD31 and CD45 staining for the lymphocytes and the established lines as indicated.

Article Snippet: Anti-FSP1 (cat. no. F4771; Sigma-Aldrich; Merck KGaA), EpCAM (cat. no. 4545; Cell Signalling Technology; Inc.), CD31 (cat. no. 303101; Biolegend; Inc.), and CD45 (cat. no. 361901; Biolegend; Inc.) were used as primary antibodies as per the dilutions instructed by the manufacturer.

Techniques: Staining